This study provides a mechanistic insight underlying the beneficial effects of tanimilast, as well as PDE4 inhibitors in general, in the treatment of lung pathologies–such as COPD–characterized by neutrophil infiltration, and supports a potential advantage in conditions that are insensitive or resistant to glucocorticoids. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.